Navigation Links
Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Date:9/18/2012

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28 – Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach – Network Biology – focusing not on gene expression but on underlying cancer signals that trigger tumor growth.

"At Merrimack Pharmaceuticals, we believe the key to finding new treatment options for cancer is to start closer to the source of the problem – with signals in the cancer cell that turn specific processes on and off, triggering tumor growth and drug resistance," said Robert J. Mulroy, President and Chief Executive Officer, Merrimack Pharmaceuticals. "By charting and modeling these molecular pathways and signals, we can identify the most sensitive points from which to attack the cancer and then develop medicines and companion diagnostics to disrupt or slow tumor growth."

Therapy and Poster Overview:

  • MM-121 is a fully human monoclonal antibody that binds to ErbB3, a protein central to the development of drug resistance and tumor growth in numerous cancers, including ovarian, breast and lung tumors. It is designed to block the signal that allows ErbB3 to bind with other proteins and trigger cell growth and drug resistance.
    • A Phase 1 Study of the Anti-ErbB3 Antibody MM-121 in Combination with Weekly Paclitaxel in Patients with Advanced Gynecological and Breast Cancers (Abstract #: 974PD)
      • Presentation: Gynecological Cancers, Sunday, Sept. 30, 2012, 1:00PM – 2:00PM CET, Hall G
  • MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell receptor. MM-111 is designed to uniquely address the tumor growth and survival signaling promoted by the ErbB2, ErbB3 and heregulin signaling complex.
    • A Phase 1 Study of MM-111; a Bispecific HER2/HER3 Antibody Fusion Protein, Combined with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors (Abstract #: 496P)
      • Poster Session: Poster Presentation III, Monday, Oct. 1, 2012, 1:00PM – 2:00PM CET, Hall XL

About Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contact:
Kathleen Petrozzelli Gallagher, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Liz Bryan, Spectrum, 202-955-6222, lbryan@spectrumscience.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
2. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
3. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
4. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
5. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
6. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
7. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
8. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
9. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
10. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
11. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... investments in recruiting top industry experts, and expanding its LATAM network and logistics ... tools for clients to manage their clinical trial projects. , The expansion will ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and data ... to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” , ... of end users facing some of the most complex data challenges in the industry,” ...
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):